At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy

GSK has committed $270 million to gain access to early-stage assets in the cancer therapy class of antibody drug conjugates. After divesting its oncology business in 2015, the company has decided to re-enter the field, focusing on therapeutic modalities like immuno-oncology, synthetic lethality, and tumor cell targeting. They are prioritizing hematological malignancies, gynecological cancers, lung…

Read More

Will CMS Crack Down on Prior Authorization?

Doctors and patients in the US are frustrated with the prior authorization process required by health insurance companies. Medicare Advantage insurers had to process an average of 1.5 prior authorization requests per patient in 2021. Legislation to regulate prior authorization has strong support from lawmakers, but a bill has not yet passed Congress. The Centers…

Read More

COVID-19 pandemic delayed socio-emotional development in young children

A study published in JAMA Pediatrics found that infants and toddlers experienced socio-emotional development delays during the COVID-19 pandemic. The study included 60,171 families enrolled in the Nurse-Family Partnership (NFP) between 2015 and 2021. The researchers examined the impact of COVID-19 on children’s socioemotional development, finding that all pandemic cohorts had higher odds of positive…

Read More
error: Content is protected !!